DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) have been assigned an average rating of “Moderate Buy” from the six research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $12.3333.

Several equities analysts recently issued reports on DMAC shares. Wall Street Zen raised DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Monday, April 20th.

Hedge Funds Weigh In On DiaMedica Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. acquired a new position in DiaMedica Therapeutics during the fourth quarter worth about $29,000. Russell Investments Group Ltd. acquired a new position in shares of DiaMedica Therapeutics during the 3rd quarter worth approximately $27,000. Farther Finance Advisors LLC acquired a new position in shares of DiaMedica Therapeutics during the 4th quarter worth approximately $34,000. Bank of America Corp DE raised its position in shares of DiaMedica Therapeutics by 3,710.3% during the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock worth $33,000 after purchasing an additional 8,274 shares during the last quarter. Finally, Truvestments Capital LLC raised its position in shares of DiaMedica Therapeutics by 112.3% during the 4th quarter. Truvestments Capital LLC now owns 9,849 shares of the company’s stock worth $78,000 after purchasing an additional 5,210 shares during the last quarter. Institutional investors and hedge funds own 10.12% of the company’s stock.

DiaMedica Therapeutics Trading Up 2.4%

DMAC stock opened at $5.46 on Friday. The firm has a 50 day moving average of $6.14 and a 200-day moving average of $7.43. DiaMedica Therapeutics has a 12-month low of $3.47 and a 12-month high of $10.42. The company has a market cap of $294.18 million, a price-to-earnings ratio of -7.69 and a beta of 0.97.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). Sell-side analysts forecast that DiaMedica Therapeutics will post -0.86 earnings per share for the current fiscal year.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.